• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献 >>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

沙美特罗替卡松对老年慢性阻塞性肺疾病合并2型糖尿病患者糖代谢及骨密度的影响

Effects of salmeterol fluticasone on the glucose metabolism and bone density of the elderly patients with chronic obstructive pulmonary disease combined with type 2 diabetes mellitus

摘要:

目的 观察沙美特罗丙酸氟替卡松吸入对老年慢性阻塞性肺疾病(COPD)合并2型糖尿病(T2DM)患者糖代谢及骨密度有无不良影响.方法 将31例老年COPD合并T2DM患者按随机数字表法分为两组,对照组14例,给予常规治疗,试验组17例,另外加用沙美特罗替卡松50/500μg每日2次,每次1吸,连续用药3个月,观察两组患者空腹血糖、餐后2h血糖、糖化血红蛋白、血浆皮质醇及骨密度水平的改变.结果 试验组患者的空腹血糖、餐后2h血糖、糖化血红蛋白、骨密度水平分别由治疗前的(5.25±0.21) mmol/L、(7.14±0.33) mmol/L、(5.58±0.26)%、(1.96±0.11)g/cm2变为治疗后的(5.31±0.27) mmol/L、( 7.22±0.29) mmol/L、(5.67±0.23)%、(2.03±0.15)g/cm2,差异无统计学意义(P>0.05);对照组患者的相应指标分别由治疗前的(5.33±0.35) mmol/L、(7.26±0.29) mmol/L、(5.62±0.19)%、(1.88±0.20) g/cm2变为治疗后的(5.36±0.31) mmol/L、(7.30±0.35)mmol/L、(5.69±0.26)%、(1.98±0.17) g/cm2,差异无统计学意义(P>0.05);两组患者组间比较差异亦无统计学意义(P>0.05).两组患者治疗前后血浆皮质醇水平比较差异无统计学意义(P>0.05).结论 沙美特罗替卡松吸入对老年COPD合并T2DM患者的糖代谢和骨密度无不良影响.

更多
abstracts:

Objective To observe the effects of salmeterol fluticasone on the glucose metabolism and bone density of the elderly patients with chronic obstructive pulmonary disease (COPD) combined with type 2 diabetes mellitus (T2DM).Methods Thirty-one patients with COPD combined with T2DM were divided into 2 groups by random digits table,14 cases in control group were given conventional therapy,17 cases in experimental group were given conventional therapy and fluticasone propionate 50/500 μg,twice a day,for 3 months.The fasting blood glucose,postprandial 2 hours glucose,glycosylated hemoglobin,plasma cortisol and bone density respectively before and after treatment were detected.Results In experimental group,the fasting blood glucose,postprandial 2 hours glucose,glycosylated hemoglobin and bone density before treatment was (5.25 ± 0.21 ) mmol/L,(7.14 ± 0.33 ) mmol/L,(5.58 ± 0.26 )%,( 1.96 ± 0.11 ) g/cm2,and after treatment was(5.31 ± 0.27 ) mmol/L,(7.22 ± 0.29 ) mmol/L,(5.67 ± 0.23 )%,(2.03 ± 0.15 ) g/cm2,there was no significant difference (P > 0.05).In control groups,the fasting blood glucose,postprandial 2 hours glucose,glycosylated hemoglobin and bone density before treatment was (5.33 ± 0.35) mmol/L,( 7.26 ± 0.29 ) mmol/L,( 5.62 ± 0.19 )%,( 1.88 ± 0.20 ) g/cm2,and after treatment was ( 5.36 ± 0.31 ) mmol/L,(7.30 ± 0.35 ) mmol/L,( 5.69 ± 0.26 )%,( 1.98 ± 0.17 ) g/cm2,there was no significant difference (P > 0.05 ).There was no significant difference in plasma cortisol before and after treatment in two groups (P >0.05).Conclusion Inhaling salmeterol fluticasone for elderly patients with COPD combined with T2DM is safe.

More
  • 浏览:226
  • 下载:32

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

扩展文献

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷